SkinBioTherapeutics PLC Appointment of Joint Broker (8892O)
02 February 2019 - 2:30AM
UK Regulatory
TIDMSBTX
RNS Number : 8892O
SkinBioTherapeutics PLC
01 February 2019
SkinBioTherapeutics plc
Appointment of Joint Broker
Manchester, UK - 1 February 2019 - SkinBioTherapeutics plc (AIM:
SBTX - "SkinBioTherapeutics" or the "Company"), a life science
company focused on skin health, announces that pursuant to the
proposed merger between SP Angel Corporate Finance LLP ("SP Angel")
and Northland Capital Partners Ltd, it has appointed SP Angel as
its Joint Broker with immediate effect.
-ENDS-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Dr. Cath O'Neill, CEO 468 2760
Doug Quinn, CFO
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Tony Rawlinson / Sandy Jamieson / Richard
Nash
SP Angel Corporate Finance (Joint Broker) Tel: +44 (0) 20 3470
Vadim Alexandre / Abigail Wayne 0470
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3621
Ben Turner / James Pope 4120
Instinctif Partners (Media Relations) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Deborah Bell 2020
SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made
on the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(R)
platform can improve the barrier effect of skin models, protect
skin models from infection and repair skin models. Proof of
principle studies have shown that the SkinBiotix(R) platform has
beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(R). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising
GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
APPBUGDDBDGBGCB
(END) Dow Jones Newswires
February 01, 2019 10:30 ET (15:30 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024